Skip to main content

Mintz Advises Biopharmaceutical Company Spero Therapeutics on Pricing of Public Offering

Mintz advised Spero Therapeutics, Inc. on the company’s pricing of an underwritten public offering. The public offering includes 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock. The public offering price of each share of common stock is $12.50 and the public offering price of each share of Series A Preferred Stock is $12,500.00. The gross proceeds to Spero from this offering are $75,000,000 prior to the deduction of any underwriting discounts and commissions.

Spero is a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections. Mintz previously advised Spero on its initial public offering (IPO) which closed in November 2017.

The Mintz team was led by Lewis Geffen and Matthew Gardella, Members in the Corporate & Securities Section. The legal team included Corporate & Securities Member Matt Tikonoff and Associate Brian Shea, Health Law Member Dianne Bourque and Tax Member Roy Gillig.